Luckily, I never bought into the hype over INO several years ago because too much seemed to be up in the air, or conveyed in a 'fluffy' and inexact manner. Kept following them though at a distance.
What little INO that I do hold I have at a cost average of ~$1.70/share, and I have only had for about 2-3 months. Seems a fair price for a company that might have themselves a successful Phase I/II trial completion under their belt. If I am wrong, I am not in too deep or overextended.
Something might still pan out for their COVID vaccine with that Chinese partner and INO is no longer footing the bill for the trials in the meantime. And their Phase I/II trial data for their glioblastoma trial last spring was interesting as well.
That being said - past management was definitely not always honest with shareholders and played very fast and loose.
News 
Market Data 
Discover 
